Clinical Anaysis Of 27 Patients With Philadelphia Positive Acute Lymphoblastic Leukemia

Objective:To study the clinical effects of imatinib and hematopoietic stem cell transplantation in Ph+ acute lymphocytic leukemia(ALL). Methods:27 new diagnosed patients with Ph+ALL,19 were assigned to induction treatment with imatinib combined with chemotherapy (8 of IVD,8 of VDLP and imatinib,3 of VDP and imatinib),22 patients after complete remission had maintenance therapy combined with imtinib,3 patients had maintenance therapy without imtinib. Followed-up the blood routine examination, bone marrow aspiration and ABL fusion gene,6 patients had hematopoietic stem cell transplantation(one was auto-HSCT). Results:The CR rate of imatinib combined was hidger than the patients without imatinib(89.5% vs 50%, P<0.05), the induction mortality rate was also higher (0 vs 12.5%, P<0.05). The median remission duration of imatinib combined and without imatinib were 10±1.4 months and 2 months(P<0.05). The remission duration at 24 months was significantly longer in patients received allo-HSCT than in those received chemotherapv only (83.3%vs 12.6%,P< 0.05), but the survival period was not significantly different(P>0.05). Conclusion:Imatinib is effective for the induction therapy of Ph+ALL. The remission duration of patients who received HSCT was obviously longer than those who received chemotherapy only.